Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
复制标题
DOI：
10.1056/nejmoa074943
复制
发表时间：
2008-03-13
影响因子：
158.5
通讯作者：
Platts-Mills, Thomas A. E.
中科院分区：
文献类型：
--
作者：
Chung, Christine H.;Mirakhur, Beloo;Platts-Mills, Thomas A. E.
背景资料：西妥昔单抗是一种抗表皮生长因子受体的鼠-人嵌合IgG 1单克隆抗体，已被批准用于结直肠癌和头颈部鳞状细胞癌。在美国的一些地区，对西妥昔单抗的过敏反应的高患病率已被报道。方法：我们分析了来自四组受试者的血清样本中针对西妥昔单抗的IgE抗体：来自76例在多个中心接受西妥昔单抗治疗的受试者的治疗前样本，主要在田纳西州、阿肯色州和北卡罗来纳州;来自田纳西州72例对照受试者的样本;来自北方加州的49名癌症对照受试者的样本;以及来自波士顿的341名女性对照受试者的样本。在这些受试者中，17名受试者的治疗前样本中发现了抗西妥昔单抗的IgE抗体; 51名无超敏反应的受试者中只有1名有此类抗体（P
Background: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States.Methods: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston.Results: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P